Wheeseong Lee’s Post

Seoul, South Korea, July 30, 2024 – Lmito Therapeutics announced today that, effective June 1, 2024, it has become a member of Johnson & Johnson Innovation – JLABS Korea. The company is working toward developing novel therapies for immunological disorders through an emerging concept of metabolic reprogramming. Lmito's groundbreaking technology focuses on modulating immunometabolisms in the inflammation microenvironment (IME). This approach has shown promise in promoting anti-inflammatory responses and reducing fibrosis, offering a dual-action approach to simultaneously address inflammation and fibrosis. By targeting these key aspects of disease progression, Lmito aims to develop more effective and safer treatments for patients suffering from chronic inflammatory and fibrotic conditions. "We are thrilled to join as an inaugural member of JLABS Korea as it marks a significant milestone in Lmito's journey," remarked Wheeseong Lee, CEO of Lmito. "The JLABS network will provide us with world-class mentorship and invaluable resources and research capabilities to accelerate Lmito's innovative approach in developing therapies for a spectrum of autoimmune diseases." The company's membership of JLABS Korea will leverage the expertise and global reach of Johnson & Johnson and the track record of JLABS in accelerating innovation across the globe. We aim to connect within innovative circles and create pathways to potential pharmaceutical industry partnerships, positioning Lmito at the forefront of biotechnological advancement. About Lmito: Lmito is a biotechnology company pioneering the modulation of cell metabolisms in the inflammation, fibrosis, and tumor microenvironments to develop innovative therapies for autoimmune diseases, fibrosis, and cancer, respectively. This innovative strategy targets critical aspects of various chronic diseases, addressing the pressing need for more effective treatments with fewer side effects in multiple conditions. By leveraging its expertise in metabolic reprogramming, Lmito aims to transform the treatment landscape for patients with limited therapeutic options. https://lnkd.in/gYbn9ZZ9.

With #BIO2024 taking place this week in San Diego, the life sciences community closes in on a mid-year check-in point. A time when thousands of the greatest scientific innovators from across the globe come together to take a pulse on the state of the industry, reflect on the first half of the year and predict what lies ahead. As the life sciences community comes together and looks ahead to what's needed to accelerate the development and delivery of modern therapeutics, they must move beyond traditional research spaces and large-scale manufacturing and global distribution centers. In my recent interview with @BioPharmaDive, I discuss how SmartLabs is helping to bridge the gap between traditional and modern drug development through our first-in-class, integrated offerings which combine reconfigurable lab infrastructure, operations, and scientific expertise. Read the full Q&A on BioPharmDive: https://lnkd.in/g_iYzUXe #SmartLabs #EnablingTheFutureOfScience #BioPharma #LabSolutions

Chinese biotech industry is growing and plays a more and more important role in life science.

If you missed last week’s article in BioPharma International about Early Analytics & PDC Modeling & Translational CRO’s by Andrew Carnegie, Head of Strategic Commercial Development at Inaphaea BioLabs, read all about this in the link below. #InAphaeaBioLabs #ScientificCommercialResearch #BioPharmaNews

Our SPATIALPlex Solutions bring innovative approaches to your biomarker and clinical development programs. Spatially visualizing drug activity with unparalleled precision, Flagship Biosciences supports discovery and target engagement decisions that transcend conventional approaches and enable vivid insights to refine drug efficacy. Learn more… https://hubs.la/Q02rq17H0 #SpatialBiology #SpatialPlexSolutions #DigitalPathology #DrugDevelopment

Discover how Lifebit is driving efficiency in drug discovery with our latest module. By harnessing external expertise and cutting-edge technologies, we're working to accelerate the path to novel therapeutics. Explore the insights in our latest white paper: https://bit.ly/3w7mQOU #DrugDiscoveryWorkflows #Pharma #Lifebit

MEPSGEN is presenting a corporate overview and update on the preclinical development of its nanomedicine candidates for Alzheimer’s disease and glioblastoma at Biotech Showcase™ 2024. Two nanomedicines MEPSGEN develops are MG-PE3, a bioinspired lipid nanoparticle that clears brain amyloid with no side effect in Alzheimer’s disease, and MG-GHC24, a drug-loaded lipid nanoparticle that interferes with cholesterol metabolism in glioblastoma. The presentation will take place on January 10th at 11:00 a.m. in Franciscan B (Ballroom Level), located inside the Hilton San Francisco Union Square, presented by Dr. YongTae Kim, CEO of MEPSGEN. We look forward to seeing you there.   🎉 https://lnkd.in/g_35M_cH (Informa Connect)   #MEPSGEN #2024_BTS #Biotech_showcase #microfluidics #nanomedicine #alzheimers_disease #alzheimers #amyloid #glioblastoma #metabolic_anticancer_drug #LNP #mRNA #vaccine #GMP #MPS #microphysiological_system

The emerging, differentiated biology of PROTACs and molecular glues hasn’t come without challenges as we make progress with these exciting modalities which hold promise as future therapies. I am pleased to share the third and final article of the undruggables series, published in Drug Discovery Online. In it I discuss some of the limitations and opportunities of existing technologies, when we apply them to these novel modalities. Read more here: https://lnkd.in/e8srHjim

Reflecting on a successful first day at the 42nd JPM Healthcare Conference with GenScript, GenScript ProBio, and Legend Biotech!   Ying Huang, CEO of Legend Biotech, shared the positive strides and future outlook of Legend Biotech's cell therapy research and development pipeline.   Looking ahead to day two, Li Chen, CEO of GenScript Probio, will present on January 10, exploring Probio's strengths in drug discovery and the CDMO field.   We will also host the GenScript Biotech Global Forum 2024, bringing together leaders from academia, regulatory agencies, enterprises, and the capital market to explore the future development of these therapies and build a platform for mutual exchange and cooperation.   Stay tuned for updates as we navigate the forefront of biotech innovation at the JPM Healthcare Conference!   Find more details here: https://lnkd.in/eVuenHDT #biotechnology #lifesciences #genetherapy #celltherapy #biotechindustry #GSforum2024

While small-molecule drug discovery continues to deliver remarkable successes, new modalities bring diversity and new perspectives, significantly expanding our capacity to address unmet treatment needs. Read my new article on the complexity of the research landscape and how software solutions can keep pace: https://bit.ly/46BeGMR P.S. Ever read something and wanted to interact more? Please share your thoughts within our short 7 question poll (https://lnkd.in/gD24GC9M)